

Risankizumab 600mg concentrate for solution for infusion and 360mg solution for injection (Skyrizi®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2534	For the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.	Available in line with local or regional guidance	15/11/2023	29/02/2024

Other Decision Specified :

Web Link : <https://www.scottishmedicines.org.uk/medicines-advice/risankizumab-skyrizi-abb-smc2534/>

Efgartigimod alfa concentrate for solution for infusion (Vyvgart®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2561	As an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHS Scotland	15/11/2023	15/11/2023

Other Decision Specified :

Web Link : <https://www.scottishmedicines.org.uk/medicines-advice/efgartigimod-alfa-vyvgart-full-smc2561/>

Mercaptamine gastro-resistant hard capsules (Procysbi®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2571	Treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	Not routinely available as not recommended for use in NHS Scotland	15/11/2023	15/11/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/mercaptamine-procysbi-2nd-resub-smc2571/				
Selpercatinib hard capsules (Retsevmo®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2573	Monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/11/2023	29/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/selpercatinib-retsevmo-full-smc2573/				

Avacopan hard capsules (Tavneos®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2578	In combination with a rituximab or cyclophosphamide regimen, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Not routinely available as there is a local preference for alternative medicines	15/11/2023	29/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/avacopan-tavneos-full-smc2578/				
Durvalumab concentrate for solution for infusion (Imfinzi®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2582	In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/11/2023	29/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/durvalumab-imfinzi-full-smc2582/				

Tafamidis 61mg soft capsules (Vyndaqel®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2585	For the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Available in line with national guidance	15/11/2023	15/11/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/tafamidis-vyndaqel-2nd-resubmission-smc2585/				
Pegunigalsidase alfa concentrate for solution for infusion (Elfabrio®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2591	For long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry Disease (deficiency of alpha-galactosidase).	Not routinely available as not recommended for use in NHS Scotland	15/11/2023	15/11/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/pegunigalsidase-alfa-elfabrio-full-smc2591/				

Bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2605	Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/11/2023	29/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/bimekizumab-bimzelx-abb-smc2605/				
Progesterone vaginal capsules (Utrogestan®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2630	Prevention of preterm birth in women with a singleton pregnancy who have a short cervix (mid-trimester sonographic cervix ≤ 25 mm) and/or a history of spontaneous preterm birth.	Not routinely available as not recommended for use in NHS Scotland	15/11/2023	15/11/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/progesterone-vaginal-capsules-utrogestan-nonsub-smc2630/				